Lenalidomide Sandoz (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This triggers enhanced T‑cell and NK‑cell activity, reduces pro‑inflammatory cytokine production, and exerts anti‑angiogenic and direct anti‑tumor effects.

The dosing regimen for Lenalidomide Sandoz is individualized by the prescribing clinician based on the specific indication, disease stage, renal function, and patient tolerance. Healthcare professionals determine the appropriate strength, frequency, and duration of therapy.

Lenalidomide is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Safety during breastfeeding has not been established, and nursing is generally discouraged while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, immunostimulatory activity, and anti‑angiogenic effects, making it a valuable option either alone or in combination regimens for patients who may not tolerate injectable therapies.

Lenalidomide Sandoz should be stored at room temperature below 25 °C, in its original packaging, and protected from moisture and direct light. Do not store in the bathroom or near heat sources, and keep the product out of reach of children.

The medication is taken orally, usually once daily, with or without food as directed by the prescriber. Patients should swallow the tablet whole with water and follow any specific timing instructions provided by their healthcare professional.

Serious risks include severe neutropenia, thrombocytopenia, venous thromboembolism, secondary primary malignancies, and rare hypersensitivity reactions. Regular monitoring of blood counts and vigilance for signs of clotting or infection are essential to mitigate these hazards.

Patients with known hypersensitivity to lenalidomide or any component of the formulation should avoid the drug. It is also contraindicated in pregnant women, and caution is advised for individuals with severe renal impairment, uncontrolled infections, or a high baseline risk of thromboembolic events.